Zanib 80mg (Zanubrutinib) is a next-generation Bruton rsquo;s Tyrosine Kinase (BTK) inhibitor manufactured by Pharma Lord. It is primarily used to treat certain blood cancers, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Zanubrutinib works by inhibiting BTK, a protein essential for the growth and survival of cancerous B cells, leading to the death of these cancer cells.
Advantages of Zanubrutinib:
- Selective BTK Inhibition: Zanubrutinib offers highly selective inhibition of BTK, reducing off-target effects and improving tolerability.
- Efficacy in Blood Cancers: Proven effectiveness in treating blood cancers like mantle cell lymphoma and chronic lymphocytic leukemia, even in cases of relapse.
- Improved Safety Profile: Compared to other BTK inhibitors, Zanubrutinib has a more favorable side effect profile, making it suitable for long-term treatment.
- Oral Administration: Available as an oral capsule, allowing for convenient administration for patients.
- Effective in High-Risk Patients: It has shown efficacy in treating high-risk patients and those resistant to other therapies.
Uses of Zanib 80mg:
- Mantle Cell Lymphoma (MCL): Zanubrutinib is indicated for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
- Chronic Lymphocytic Leukemia (CLL): Used in the treatment of CLL and small lymphocytic lymphoma (SLL) to inhibit cancer cell growth.
- Waldenstr ouml;m rsquo;s Macroglobulinemia (WM): Also used for treating WM, a rare type of non-Hodgkin lymphoma.